HCV treatment found safe and effective in individuals with kidney disease

September 7, 2017, American Society of Nephrology
This image shows a cross section of a kidney. Credit: Holly Fischer/Wikipedia

A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN), also found that treatment may help improve some patients' kidney function.

HCV infection—which often causes liver disease—is common in with CKD, and it increases their risk of progressing to failure. Sofosbuvir is a potent direct-acting antiviral therapy against HCV, but concerns about potential kidney toxicity have been raised, particularly in patients with CKD.

To determine the safety and efficacy of sofosbuvir in patients with CKD, Meghan Sise, MD, MS (Massachusetts General Hospital) and her colleagues studied 98 patients with stages 1-3 CKD who received sofosbuvir-based therapy in a large healthcare system.

Overall sustained virologic response (which is synonymous with cure of HCV infection) was 81%, and average kidney function while on the treatment was stable. Patients with more advanced CKD were more likely to be cured of HCV infection than those with mild CKD. In addition, patients with advanced CKD who were cured of HCV infection experienced an improvement in their kidney function following treatment. Sofosbuvir was reasonably well tolerated: were common (81%), but serious adverse events (17%) and treatment discontinuations (8%) were uncommon. Also, there was no detectable effect of the degree of CKD on the rate of adverse events.

Larger studies are needed to determine if eradication of HCV with direct-acting antiviral therapy slows or prevents progression to end stage kidney disease in patients with CKD and HCV.

"The use of direct-acting antiviral therapy in patients with Hepatitis C infection has transformed the illness into a curable one. This study shows that these medications can be safely and effectively used in patients with stage 1-3 ," said Dr. Sise.

In an accompanying editorial, Richard Johnson, MD (University of Colorado) and Michiko Shimada, MD, PhD (Hirosaki University Graduate School of Medicine, in Japan) noted that there are other antiviral drugs that are effective in patients with CKD and HCV, and unlike sofosbuvir, they are not eliminated by the kidneys. Therefore, additional research on the effects of different antivirals in patients with compromised are needed. "We predict that HCV, like hepatitis B virus and HIV, will slowly disappear as a major medical problem for patients with renal disease," they wrote.

Explore further: Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

More information: "Effect of Sofosbuvir-based Hepatitis C Virus Therapy on Kidney Function in Patients with Chronic Kidney Disease," Clinical Journal of the American Society of Nephrology (2017). DOI: 10.2215/CJN.02510317

Related Stories

Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

January 10, 2017
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II ...

Non-specialists can expand hepatitis C treatment access

August 8, 2017
(HealthDay)—Non-specialists, including primary care providers (PCPs) and nurse practitioners (NPs), safely and effectively administer direct-acting antiviral therapy for hepatitis C virus (HCV) to patients seen in federally ...

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

November 4, 2014
(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Genetic markers may predict which HCV, cirrhosis patients improve with treatment

May 6, 2017
Genotyping of patients with advanced cirrhosis from hepatitis C virus could help health-care professionals predict the likelihood of improvement after successful hepatitis C treatment, thus minimizing the need for liver transplants. ...

Improved glycemic control with eradication of hepatitis C

July 7, 2017
(HealthDay)—For patients with type 2 diabetes, direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) is associated with improved glycemic control and reduced antidiabetic medication use, according to a study ...

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.